An examination of Cox-2 class drugs for assessing Merck's decision to withdraw Vioxx.

This is a study of international disparities in prescription drug prices between the United States and five OECD nations (Australia, Canada, France, Germany, and the U.K.).

While critics have pronounced the Medicare prescription drug discount card program a failure, Antos and Pinell find that the evidence proves otherwise.

Joseph Antos and Ximena Pinell find that enrollment in the Medicare prescription drug discount programrequires better consumer access to program information.

Post-approval drug safety surveillance is an extraordinarily difficult task.The Vioxx episode has probably made it more difficult for the Food and Drug Administration to do its job.

Economics and regulatory policy are driving pharmaceutical manufacturers away from the market for treating ordinary medical conditions toward drugs for major health problems.

New research findings and a thorough reassessment of older research indicate that drugs like Vioxx can have many important benefits and great potential for addressing serious problems.